C17orf80

Across TCGA pan-cancer cohorts, C17orf80 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C17orf80 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher C17orf80 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated C17orf80 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, HNSC, and CCRCC are the cancer types where C17orf80 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	1.000	0.856	.002	15	view →
HNSC	OS	Quartile	All	0.772	0.930	.014	12	view →
CCRCC	DFS	Tertile	IV	0.207	0.961	.024	6	view →
PDAC	DFS	Median	II,III,IV	0.628	0.774	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C17orf80–LSCC (DFS)

Open the LSCC breakdown →